Evolus (EOLS)
(Delayed Data from NSDQ)
$12.86 USD
-0.15 (-1.15%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $12.86 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Brokerage Reports
0 items in cart
Evolus, Inc. [EOLS]
Reports for Purchase
Showing records 21 - 40 ( 51 total )
Company: Evolus, Inc.
Industry: Medical - Products
Solid Quarter Bolstered by Strong Aesthetics Market; Reiterate Buy, Lower PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
Company: Evolus, Inc.
Industry: Medical - Products
Growth in First Unencumbered Quarter as Evolus Looks to Europe; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
Returning to Where We Left Off Before the ITC and COVID; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
Government Stimulus Should Stimulate Demand for Jeuveau
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
Evolus Looks to the Future on 4Q Call; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
ITC Dust Finally Settles with Daewoong Transactions Bolstering Balance Sheet; Reiterate Buy; PT to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
Jeuveau Set for Growth With ITC in Rear View Mirror; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
Cloud of Uncertainty Clears as Evolus Settles with AbbVie and Medytox, Ending Jeuveau IP Dispute; Reit Buy, PT to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
Company: Evolus, Inc.
Industry: Medical - Products
Down But Not Out: ITC Bans Jeuveau Import for 21 Months But Settlement Seems Likely; Reiterate Buy, Lower PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
Jeuveau Shows Resilience, All Eyes on ITC Case; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
Jeuveau Beats Expectations Showing Resilience in the Face of COVID-19; Reiterate Buy, Raise PT to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
Initial ITC Ruling Against Evolus; Reiterate Buy But Lowering PT to $7 from $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
1Q Not Surprisingly Noisy, But Company Remains Well Positioned for Long-Term Growth; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
Company: Evolus, Inc.
Industry: Medical - Products
Social Distancing Takes a Toll; Lower Estimates and PT Goes to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
Launch Moves to Next Stage, Still on Track to Achieve #2 Position; Tweak Target to $31, Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
Launch Remains Strong, Though ITC Overhang Persists; Tweak Target to $34, Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
Jeuveau Maintains Momentum to Close ''19; Stage Set for Strong 2020
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D